United States: Only Having The Pieces Of A Jigsaw Puzzle Isn't Enough - They Have To Be Assembled Together

Decision: Brigham and Women's Hospital, Inc. v. Perrigo Co., --F.3d __ (Fed. Cir. Feb. 28, 2019) (non-precedential) (LOURIE, O'Malley, and Stoll)

Background:   Brigham's U.S. Patent No.  5,229,137 ('137 patent) (now expired) claimed a method for treating episodic heartburn, in particular, by co-administering an antacid and H2-blocker to achieve a certain clinical result: "immediate and sustained relief" from pain.

Brigham's asserted claim included reference points for the "immediate and sustained relief:" the relief had to last longer than treatment with only the antacid and it had to act faster than and last about as long as treatment with only the histamine H2-receptor antagonist.

Claim 1 reads:

1. A method of providing immediate and sustained relief from pain, discomfort and/or symptoms associated with episodic heartburn in a human, said method comprising: orally administering to a human together or substantially together an antacid in an amount effective to substantially neutralize gastric acid and a histamine H2-receptor antagonist in an amount effective to substantially inhibit or block gastric acid secretion for providing the human with immediate and sustained relief from pain, discomfort and/or symptoms associated with episodic heartburn, the immediate and sustained relief provided lasting longer in duration than when the human is orally treated with only the antacid and the immediate and sustained relief provided being faster than and lasting at least about as long in duration as when the human is orally treated with only the histamine H2-receptor antagonist.

Although Perrigo sent Brigham a Paragraph IV notice mentioning the '137 patent when it filed its ANDA, Brigham's exclusive licensee, Johnson & Johnson, did not assert the '137 patent against Perrigo, rather sued Perrigo on another patent not involved in this lawsuit. Perrigo prevailed in the lawsuit and launched its generic product in 2008.  In 2013, Brigham sued Perrigo for infringement of the'137 patent.

Brigham argued that the clinical data demonstrated that Pepcid Complete® provides immediate relief, and since Perrigo's generic product has the same active ingredients and dosages as Pepcid Complete®, Perrigo's generic product must also provide immediate relief.

The district court construed the claim limitation "immediate and sustained relief" according to the express definition provided in the specification, providing that the relief start within about 5-10 minutes and last about 4-6 hours:

It should therefore be appreciated that by the term "immediate and sustained relief," it means herein immediate, temporary and sustained relief which starts within about 5-10 minutes following ingestion of the active ingredients and continues and remains constant for at least about 4-6 hours after ingestion of the active ingredients; the actual ingredients being an antacid and a histamine H2-receptor antagonist.

A jury found that the asserted claims of the '137 patent were not invalid, that Perrigo's generic product infringed each asserted claim, and that Perrigo's infringement was willful. The jury awarded Brigham damages of about $10 million.

The district court denied JMOL of invalidity and granted JMOL of noninfringement. "[T]he court determined that the clinical evidence did not demonstrate that Pepcid Complete® provided immediate relief from episodic heartburn." Therefore, Perrigo's generic product with the same active ingredients and dosages did not infringe.

Issue on Appeal: Did Pepcid Complete® (and therefore Perrigo's generic product) meet the "immediate relief" claim limitation?

Outcome: Affirmed:  No infringement.

The district court's claim construction based, as it was, expressly on the specification, was undisputed. The Federal Circuit found sufficient evidence supported the district court's conclusion of noninfringement. The patent owner, trying to carry its burden on infringement, pointed out that the active ingredients and dosages of the branded and generic product were the same. The evidence provided by Brigham (three clinical studies from its NDA), however, was found to not in fact show that the branded product provided immediate relief within 5-10 minutes. Other evidence showed "adequate relief" at 15 minutes, not "immediate relief within 5-10 minutes" in accord with the claim construction. Further testimony by the inventor was "uncorroborated, conclusory, and interested testimony [which was] insufficient to carry Brigham's burden of proof and to sustain the jury verdict." Specifically, the inventor testified, unsuccessfully to prove infringement, that he knew the allegedly infringing product met the claimed limitations because he took the medicine himself.

Prosecution Takeaways:

This case provides an example of having all the pieces of a jigsaw puzzle, but not assembling them together properly to complete the puzzle.

First, if the patent owner has clinical data it is providing to the FDA in its NDA, counsel should work carefully and diligently, in representing the patent owner, to file a U.S. provisional patent application setting forth the clinical studies and results, preferably before the results are made public. If that timing is not achieved, all may not be lost, however. In the U.S., a patent application filed within a year of the publication of the results may avoid prior art effects of the clinical results, at least in the U.S.

Align the claims to the results of the clinical trial(s). Importantly, negotiate with the FDA so that the label contains a section setting forth the clinical studies and results and also cross references those clinical studies and results in the Indications and Usage section. Sanofi and Vanda, above, are examples where all of such considerations were taken into account, and the jigsaw puzzle was completely assembled. In those two cases, the timing, pieces of the specification and claims, clinical studies, clinical results, and appropriate references in the Indications and Usage section of the label were all carefully assembled to complete the puzzle. The Brigham case apparently had all the pieces available, but the label did not provide a sufficient link to the patent specification and claims were not aligned with the clinical results. And without label evidence of induced infringement or any evidence establishing literal infringement, the patent owner was unable to prove that its product (and therefore the Perrigo product) satisfied all claim limitations to establish literal infringement.

Second, as is probably evident from the above, if the clinical data, label, and claims are carefully aligned and assembled, there may be very strong grounds for proving induced infringement based on the generic manufacturer's label. In this Brigham case, the patent owner only alleged literal infringement of Perrigo's commercial product and had no induced infringement (or DOE) position to fall back on. As noted above, the label apparently did not provide a sufficient link to the patent specification and claims, and the claims were not aligned with the clinical results.

Finally, the patent owner in this case provided a definition for the claim terms in the specification, and the claims were construed accordingly. To the extent that definitions can constitute a sharp sword, this was a case where the patentee died by that sword. To be sure, it can be observed that the patent owner obtained a claim construction desired by the patent specification. But that desired claim construction was not part of a broader strategic context in which the patent owner developed the record sufficiently, analogously to Sanofi and Vanda, so as to be able to prove, relatively easily, infringement of the '137 patent, issued in 1993, by the product that Perrigo launched in 2008, i.e., years after the patent was granted. Clearly, in complex matters such as this one, approaching the claim drafting process with visionary "Nostradmus" insight in view of what will ultimately be in the label, can be difficult but highly useful if successful.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
26 Mar 2019, Other, Frankfurt, Germany

Finnegan is a Gold sponsor of the Automotive Legal & IP World Summit, hosted by Encom Global. Finnegan partner Lionel Lavenue will join the panel discussion “Identifying Opportunities to Patent Inventions Arising from Digital and Connected Technologies."

26 Mar 2019, Other, Washington, DC, United States

Finnegan is a Gold sponsor of the Automotive Legal & IP World Summit, hosted by Encom Global.

28 Mar 2019, Conference, New York, United States

Finnegan is an Executive Partner sponsor of the eleventh annual Corporate IP Counsel Forum, hosted by World Congress.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
 
Email Address
Company Name
Password
Confirm Password
Country
Position
Industry
Mondaq Newsalert
Select Topics
Select Regions
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions